新型口服抗凝剂相关的临床挑战：药物相互作用与监测 - Suppr

Suppr

超能文献

Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring.

作者信息

Altena Renske, van Roon Eric, Folkeringa Richard, de Wit Harry, Hoogendoorn Mels

出版信息

Haematologica. 2014 Feb;99(2):e26-7. doi: 10.3324/haematol.2013.097287.

DOI:10.3324/haematol.2013.097287

PMID:24497568

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3912982/

Abstract

摘要

相似文献

Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring.

Haematologica. 2014 Feb;99(2):e26-7. doi: 10.3324/haematol.2013.097287.

Rivaroxaban: a novel anticoagulant.

Indian J Med Sci. 2010 Nov;64(11):520-8.

[Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].

Lakartidningen. 2014;111(24):1064-8.

Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.

BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.

Rivaroxaban: a novel, oral, direct factor Xa inhibitor.

Pharmacotherapy. 2009 Feb;29(2):167-81. doi: 10.1592/phco.29.2.167.

Evaluation of Trends of Inpatient Hospitalisation for Significant Haemorrhage in Patients Anticoagulated for Atrial Fibrillation before and after the Release of Novel Anticoagulants.

Heart Lung Circ. 2015 Jan;24(1):94-7. doi: 10.1016/j.hlc.2014.06.013. Epub 2014 Jul 3.

Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF.

Eur Heart J. 2014 Jan;35(4):242-9. doi: 10.1093/eurheartj/eht492. Epub 2013 Dec 2.

Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.

Europace. 2014 Aug;16(8):1137-44. doi: 10.1093/europace/euu007. Epub 2014 Feb 18.

Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.

Semin Thromb Hemost. 2007 Jul;33(5):515-23. doi: 10.1055/s-2007-982083.

Novel oral anticoagulants: a review of the literature and considerations in special clinical situations.

Hosp Pract (1995). 2013 Feb;41(1):8-18. doi: 10.3810/hp.2013.02.1008.

引用本文的文献

DOAC drug interactions management resource.

Can Pharm J (Ott). 2022 Sep 20;155(6):315-325. doi: 10.1177/17151635221116100. eCollection 2022 Nov.

Biomaterials-Enabled Antithrombotics: Recent Advances and Emerging Strategies.

Mol Pharm. 2022 Dec 5;19(12):4453-4465. doi: 10.1021/acs.molpharmaceut.2c00626. Epub 2022 Sep 23.

Drug Interactions Affecting Oral Anticoagulant Use.

Circ Arrhythm Electrophysiol. 2022 Jun;15(6):e007956. doi: 10.1161/CIRCEP.121.007956. Epub 2022 May 27.

Novel Drug Interaction index and Risk of Mortality in Older Patients With Atrial Fibrillation Receiving Non Vitamin K Oral Anticoagulants (NOEL Drug).

Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211038685. doi: 10.1177/10760296211038685.

Prediction of Rivaroxaban-Rifampin Interaction After Major Orthopedic Surgery: Physiologically Based Pharmacokinetic Modeling and Simulation.

Front Pharmacol. 2021 Jul 23;12:706781. doi: 10.3389/fphar.2021.706781. eCollection 2021.

Rivaroxaban for Treatment of Left Ventricular Thrombus: A Case Report.

Am J Case Rep. 2021 Jun 25;22:e932140. doi: 10.12659/AJCR.932140.

Drug-Drug Interactions Leading to Adverse Drug Reactions with Rivaroxaban: A Systematic Review of the Literature and Analysis of VigiBase.

J Pers Med. 2021 Mar 30;11(4):250. doi: 10.3390/jpm11040250.

Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review.

Thromb Res. 2020 Oct;194:240-245. doi: 10.1016/j.thromres.2020.08.016. Epub 2020 Aug 11.

Effects of ticagrelor on the pharmacokinetics of rivaroxaban in rats.

Pharm Biol. 2020 Dec;58(1):630-635. doi: 10.1080/13880209.2020.1785510.

Calculated parenteral initial therapy of bacterial infections: Antibiotic treatment in the elderly.

GMS Infect Dis. 2020 Mar 26;8:Doc05. doi: 10.3205/id000049. eCollection 2020.

本文引用的文献

Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.

Clin Pharmacokinet. 2011 Oct;50(10):675-86. doi: 10.2165/11595320-000000000-00000.

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

N Engl J Med. 2011 Sep 8;365(10):883-91. doi: 10.1056/NEJMoa1009638. Epub 2011 Aug 10.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验